Skip to main content
SpringerLink
Log in

Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis

Do the Known Risks Now Outweigh the Benefits?

  • Leading Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Since the introduction in the 1970s of treatment with oral psoralens with longwave ultraviolet radiation in the A range (PUVA), there has been an increasing concern about the long term carcinogenic effect of the therapy. The main indication for PUVA is psoriasis, a common, chronic and intractable skin disease that affects 1 to 3% of the world’s population. The effectiveness of PUVA in inducing and maintaining the remission of severe psoriasis has been amply documented. Although psoriasis is not a life-threatening disorder, it may be associated with restriction of activities and days lost to hospitalisation. Therefore, a number of systemic treatments such as methotrexate and cyclosporin have been used. None of these treatments has been as carefully studied for long term adverse effects as PUVA.

The short-term adverse effects of PUVA are generally well known and tolerated. The major mid-term adverse effect, squamous cell carcinoma of the skin, has been well documented in a number of large-scale epidemiological studies that have led to recommendations such as to restrict the lifetime number of treatments. Although squamous cell carcinoma is potentially life-threatening, it is usually slow growing and can be adequately managed by proper surveillance, treatment and follow-up.

The situation is quite different for malignant melanoma, which is often fast growing and fatal. Except for anecdotal reports, malignant melanoma has not been observed in PUVA patients until recently. However, a report of a cohort of 1380 patients with psoriasis has concluded that about 15 years after the first treatment the risk of melanoma is increased approximately 5-fold in patients treated with high doses. Although this report needs to be confirmed by other multicentre trials, it is alarming since the association between exposure to ultraviolet light and development of melanoma is well established both in humans and in experimental animals. Until this study is validated, it is recommended that the guidelines for PUVA therapy should be rigorously followed and that the contraindications should be extended to include history or family history of melanoma and patients who have already received >200 treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Stern RS, Nichols KT, Väkevä LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 1997; 336(15): 1041–5

    Article  PubMed  CAS  Google Scholar 

  2. Frenk E. Malignant melanoma in a patient with severe psoriasis treated by oral methoxsalen photochemotherapy. Dermatologica 1983; 167(3): 152–4

    Article  PubMed  CAS  Google Scholar 

  3. Marx JL, Auerbach R, Possick P, et al. Malignant melanoma in situ in two patients treated with psoralens and ultraviolet A. J Am Acad Dermatol 1983; 9(6): 904–11

    Article  PubMed  CAS  Google Scholar 

  4. Kemmet D, Reshad H, Baker H. Nodular malignant melanoma and multiple squamous cell carcinomas in a patient treated by photochemotherapy for psoriasis. BMJ 1984; 289: 1498

    Article  Google Scholar 

  5. Johnsen J. Melanoma and psoralens and ultraviolet A. J Am Acad Dermatol 1984; 11(1): 143

    Article  Google Scholar 

  6. Binet O, Bruley C, Beltzer-Garelly E, et al. Malignant melanome malin après traitement par rayons ultraviolets A et Psoralène. Presse Med 1985; 14(35): 1842

    PubMed  CAS  Google Scholar 

  7. Gupta AK, Stern R S, Swanson N A, et al. Cutaneous melanomas in patients treated with psoralens plus ultraviolet A. J Am Acad Dermatol 1988; 19: 67–76

    Article  PubMed  CAS  Google Scholar 

  8. Bergner T, Przybilla B. Malignant melanoma in association with phototherapy. Dermatology 1992; 184: 59–61

    Article  PubMed  CAS  Google Scholar 

  9. Haciyakupoglu G, Varinli I, Memisoglu H, et al. PUVA treatment and choroidal malignant melanoma. Acta Ophthalmologica 1993; 71: 846–9

    Article  PubMed  CAS  Google Scholar 

  10. Reseghetti A, Tribbia G, Locati L, et al. Cutaneous malignant melanoma appearing during photochemotherapy of mycosis fungoides. Dermatology 1994; 189: 75–7

    Article  PubMed  CAS  Google Scholar 

  11. Camp R. Psoriasis. In: Champion R, Burton J, Ebling F, editors. Textbook of dermatology. Oxford: Blackwell, 1992: 1391–2

    Google Scholar 

  12. Kreuger GG. Psoriasis: current concepts of its etiology and pathogenesis. In: Dobson RL, Thiers BH, editors. 1981 Yearbook of dermatology. Chicago: Yearbook Medical Publishers, 1981: 13–70

    Google Scholar 

  13. Parrish JA, Fitzpatrick TB, Tanenbaum L, et al. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 1974; 291: 1207–11

    Article  PubMed  CAS  Google Scholar 

  14. Hell E, Hodgson C, Manna V. Psoralen photochemotherapy of psoriasis. Br J Dermatol 1979; 101: 293–8

    Article  PubMed  CAS  Google Scholar 

  15. Heneseler T, Wolff K, Hönigsman H, et al. Oral 8-methoxypsoralen photochemotherapy of psoriasis. Lancet 1981; I: 853–7

    Article  Google Scholar 

  16. Klaber M, Baker H, Johnson-Smith J, et al. Photochemotherapy of psoriasis in a general hospital. Br J Dermatol 1979; 101 Suppl. 17: 12–3

    Google Scholar 

  17. Lakshmipathi T, Gould PW, MacKenzie LA, et al. Photochemotherapy in the treatment of psoriasis. Br J Dermatol 1977; 96: 587–94

    Article  PubMed  CAS  Google Scholar 

  18. Melski JW, Tanenbaum L, Parrish JA, et al. Oral methoxsalen photochemotherapy for the treatment of psoriasis. J Invest Dermatol 1977; 68: 328–35

    Article  PubMed  CAS  Google Scholar 

  19. Roenigk HH, Farber EM, Storrs F, et al. Photochemotherapy for psoriasis. Arch Dermatol 1979; 115: 576–9

    Article  Google Scholar 

  20. Siddiqui AH, Cormane RH. Initial photochemotherapy of psoriasis with orally administered 8-methoxypsoralen and longwave ultraviolet light (PUVA). Br J Dermatol 1979; 100: 247–50

    Article  PubMed  CAS  Google Scholar 

  21. Swanbeck G, Thyresson-Hök M, Bredberg A, et al. Treatment of psoriasis with oral psoralens and longwave ultraviolet light. Acta Derm Venereol 1975; 55: 367–76

    PubMed  CAS  Google Scholar 

  22. Wolff K, Fitzpatrick TB, Parrish JA, et al. Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol 1976; 112: 943–50

    Article  PubMed  CAS  Google Scholar 

  23. Danno K, Horio T, Ozaki M, et al. Topical 8-methoxypsoralen photochemotherapy of psoriasis. Br J Dermatol 1983; 108: 519–24

    Article  PubMed  CAS  Google Scholar 

  24. Fischer T, Alsins J. Treatment of psoriasis with trioxsalen baths and dysprosium lamps. Acta Derm Venereol 1976; 56: 383–90

    PubMed  CAS  Google Scholar 

  25. Weber G. Combined 8-methoxypsoralen and black light therapy of psoriasis. Br J Dermatol 1974; 90: 317–23

    Article  PubMed  CAS  Google Scholar 

  26. Berenbaum M, Feeny P. Toxicity of angular furanocoumarins to swallowtail butterflies: escalation in a coevolutionary arms race? Science 1981; 212: 927–9

    Article  PubMed  CAS  Google Scholar 

  27. Pathak MA, Krämer DM. Photosensitization of skin in vivo by furocoumarins (psoralens). Biochim Biophys Acta 1969; 195: 197–206

    Article  PubMed  CAS  Google Scholar 

  28. Cole RS. Light-induced cross-linking of DNA in the presence of a furocoumarin (psoralen). Biochim Biophys Acta 1970; 217: 30–9

    Article  PubMed  CAS  Google Scholar 

  29. Dall’Acqua F, Marciani S, Ciavatta L, et al. Formation of interstrand cross-linkings in the photoreactions between furocoumarins and DNA. Z Naturforsch (B) 1971; 26: 561–9

    Google Scholar 

  30. Caffierris S, Zarebska Z, DallAcqua F. Psoralen photosensitization: damages to nucleic acid and membrane lipid components. Acta Biochem Pol 1996; 43: 241–6

    Google Scholar 

  31. Gasparro FP, Felli A, Schmitt IM. Psoralen photobiology: the relationship between DNA damage, chromatin structure, transcription, and immunogenic effects. Recent Results Cancer Res 1997; 143: 101–27

    Article  PubMed  CAS  Google Scholar 

  32. Drake LA, Ceilly RI, Dorner W, et al. Guidelines of care for phototherapy and photochemotherapy. J Am Acad Dermatol 1994; 31: 643–8

    Article  Google Scholar 

  33. Morison WL, Wimberly J, Parrish JA, et al. Abnormal lymphocyte function following long-term PUVA therapy for psoriasis. Br J Dermatol 1983; 108: 445–50

    Article  PubMed  CAS  Google Scholar 

  34. Friedmann PS. Disappearance of epidermal Langerhans cells during PUVA therapy. Br J Dermatol 1981; 105: 219–21

    Article  PubMed  CAS  Google Scholar 

  35. Friedmann PS, Rogers S. Photochemotherapy of psoriasis. J Invest Dermatol 1980; 74: 440–3

    Article  PubMed  CAS  Google Scholar 

  36. Guilhou J-J, Clot J, Guillot B, et al. Immunological aspects of psoriasis. Br J Dermatol 1980; 102: 173–8

    Article  PubMed  CAS  Google Scholar 

  37. Haftek M, Glinski W, Jablonska S, et al. T lymphocyte E rosette function during photochemotherapy (PUVA) of psoriasis. J Invest Dermatol 1979; 72: 214–8

    Article  PubMed  CAS  Google Scholar 

  38. Morhenn VB, Benike CJ, Engleman EG. Inhibition of cell mediated immune responses by 8-methoxypsoralen and longwave ultraviolet light. J Invest Dermatol 1980; 75: 249–52

    Article  PubMed  CAS  Google Scholar 

  39. Moscicki R, Morison WL, Parrisch JA, et al. Reduction of the fraction of circulation helper-inducer T cells identified by monoclonal antibodies in psoriatic patients. J Invest Dermatol 1982; 79: 205–8

    Article  PubMed  CAS  Google Scholar 

  40. Moss C, Friedmann PS, Shuster S. How does PUVA inhibit delayed cutaneous hypersensitivity? Br J Dermatol 1982; 107: 511–6

    Article  PubMed  CAS  Google Scholar 

  41. Okamoto H, Horio T. The effect of 8-methoxypsoralen and long-wave ultraviolet light on Langerhans cell. J Invest Dermatol 1981; 77: 345–6

    Article  PubMed  CAS  Google Scholar 

  42. Strauss GH, Greaves M, Price M, et al. Inhibition of delayed hypersensitivity reaction in skin (DNCB test) by 8-methoxypsoralen photochemotherapy. Lancet 1980; II: 556–9

    Article  Google Scholar 

  43. Vella Briffa D, Parker D, Tosca N, et al. The effect of photochemotherapy (PUVA) on cell mediated immunity in the guinea pig. J Invest Dermatol 1981; 77: 377–80

    Article  Google Scholar 

  44. Hönigsmann H, Jaschke E, Gschnait F, et al. 5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis. Br J Dermatol 1979; 101: 369–78

    Article  PubMed  Google Scholar 

  45. Langner A, Wolska H, Kowalski J, et al. Photochemotherapy (PUVA) and psoriasis: comparison of 8-MOP and 8-MOP/5-MOP. Int J Dermatol 1976; 15: 688–9

    Article  PubMed  CAS  Google Scholar 

  46. Tanew A, Ortel B, Rappersberger K, et al. 5-Methylpsoralen (Bergapten) for photochemotherapy. J Am Acad Dermatol 1988; 18: 333–8

    Article  PubMed  CAS  Google Scholar 

  47. Young AR, Magnus IA, Davies AC, et al. A comparison of the phototumorigenic potential of 8-MOP and 5-MOP in hairless albino mice exposed to solar simulated radiation. Br J Dermatol 1983; 108: 507–18

    Article  PubMed  CAS  Google Scholar 

  48. Dubertret L, Averbeck D, Zajdela F, et al. Photochemotherapy (PUVA) of psoriasis using 3-carbethoxypsoralen, a noncarcinogenic compound in mice. Br J Dermatol 1979; 101: 379–89

    Article  PubMed  CAS  Google Scholar 

  49. Abel EA, Goldberg LH, Farber EM. Treatment of palmoplantar psoriasis with topical methoxsalen plus long-wave ultraviolet light. Arch Dermatol 1980; 116: 1257–61

    Article  PubMed  CAS  Google Scholar 

  50. Mizuno N, Uematsu S, Ohno M. Methoxsalen and irradiation: treatment for Pustulosis palmaris et plantaris. Arch Dermatol 1976; 112: 883–4

    Article  Google Scholar 

  51. Hannuksela M, Karvonen J. Trioxsalen bath plus UVA effective and safe in the treatment of psoriasis. Br J Dermatol 1978; 99: 703–7

    Article  PubMed  CAS  Google Scholar 

  52. Salo OP, Lassus A, Taskinen J. Trioxsalen bath plus UVA treatment of psoriasis. Acta Derm Venereol 1981; 61: 551–4

    PubMed  CAS  Google Scholar 

  53. Lüftl M, Degitz K, Plewig G, et al. Psoralen bath plus UVA therapy: possibilities and limitations. Arch Dermatol 1997; 133: 1597–603

    Article  PubMed  Google Scholar 

  54. Lindelöf B, Sigurgeirsson B. PUVA treatment in Sweden. Acta Derm Venereol 1992; 169 Suppl.: 1–6

    Google Scholar 

  55. O’Neal MA, Griffin AC. The effect of oxypsoralen upon ultraviolet carcinogenesis in albino mice. Cancer Res 1957; 17: 911–6

    PubMed  Google Scholar 

  56. Hakim RE, Griffin AC, Knox JM. Erythema and tumor formation in methoxsalen-treated mice exposed to fluorescent light. Arch Dermatol 1960; 82: 572–7

    Article  PubMed  CAS  Google Scholar 

  57. Forbes PD, Davies RE, Urbach R. Phototoxicity and photocarcinogenesis: comparative effects of anthracene and 8-methoxypsoralen in the skin of mice. Fed Cosmet Toxicol 1976; 14: 303–6

    Article  CAS  Google Scholar 

  58. Dunnick JK, Forbes PD, Eustis SL, et al. Tumors of the skin in the HRA/Skh mouse after treatment with 8-methoxypsoralen and UVA radiation. Fundam Appl Toxicol 1991; 16: 92–102

    Article  PubMed  CAS  Google Scholar 

  59. Hönigsmann H, Wolff K, Gschnait F, et al. Keratoses and non-melanoma skin tumors in long-term photochemotherapy (PUVA). J Am Acad Dermatol 1980; 3: 406–14

    Article  PubMed  Google Scholar 

  60. Roenigk HH, Caro WA. Skin cancer in the PUVA-48 cooperative study. J Am Acad Dermatol 1981; 4: 319–24

    Article  PubMed  Google Scholar 

  61. Lindskov R. Skin carcinomas and treatment with photochemotherapy (PUVA). Acta Denn Venereol 1983; 63: 223–6

    CAS  Google Scholar 

  62. Henseler T, Christophers E. Risk of skin tumors in psoralen- and ultraviolet A-treated patients. Natl Cancer Inst Monogr 1984; 66: 217–9

    PubMed  CAS  Google Scholar 

  63. Reshad H, Challoner F, Pollock DJ, et al. Cutaneous carcinoma in psoriatic patients treated with PUVA. Br J Dermatol 1984; 110: 299–305

    Article  PubMed  CAS  Google Scholar 

  64. Stern RS, Laird N, Melski J, et al. Cutaneous squamous cell carcinoma in patients treated with PUVA. N Engl J Med 1984; 310: 1156–61

    Article  PubMed  CAS  Google Scholar 

  65. Eskelinen A, Halme K, Lassus A, et al. Risk of cutaneous carcinoma in psoriatic patients treated with PUVA. Photodermatology 1985; 2: 10–4

    PubMed  CAS  Google Scholar 

  66. Henseler T, Christophers E, Hönigsmann H, et al. Skin tumors in the European PUVA study. J Am Acad Dermatol 1987; 16: 108–16

    Article  PubMed  CAS  Google Scholar 

  67. Torinuki W, Tagami H. Incidence of skin cancer in Japanese psoriatic patients treated with either methoxsalen phototherapy, Goeckerman regimen or both therapies. J Am Acad Dermatol 1988; 18: 1278–81

    Article  PubMed  CAS  Google Scholar 

  68. Forman AB, Roenigk HH, Caro WA, et al. Long-term follow-up of skin cancer in the PUVA-48 cooperative study. Arch Dermatol 1989; 125: 515–9

    Article  PubMed  CAS  Google Scholar 

  69. Bruynzeel I, Bergman W, Hartevelt HM, et al. High single-dose European PUVA regimen also causes an excess of non-melanoma skin cancer. Br J Dermatol 1991; 124: 49–55

    Article  PubMed  CAS  Google Scholar 

  70. Lindelöf B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer: a large-scale epidemiological study. Lancet 1991; 338: 91–3

    Article  PubMed  Google Scholar 

  71. Chuang T, Heinrich LA, Schultz MD, et al. PUVA and skin cancer. J Am Acad Dermatol 1992; 26: 173–7

    Article  PubMed  CAS  Google Scholar 

  72. Olsen JH, Moller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992; 27: 716–22

    Article  PubMed  CAS  Google Scholar 

  73. Tanew A, Hönigsmann H, Ortel B, et al. Nonmelanoma skin tumors in longterm photochemotherapy treatment of psoriasis. J Am Acad Dermatol 1986; 15: 960–5

    Article  PubMed  CAS  Google Scholar 

  74. Lever LR, Farr PM. Skin cancers or premalignant lesions occur in half of high-dose PUVA patients. Br J Dermatol 1994; 131: 215–9

    Article  PubMed  CAS  Google Scholar 

  75. Maier H, Schemper M, Ortel B, et al. Skin tumors in photochemotherapy for psoriasis: a single-center follow-up of 496 patients. Dermatology 1996; 193: 185–91

    Article  PubMed  CAS  Google Scholar 

  76. Lindelöf B, Sigurgeirsson B. PUVA and cancer: a case-control study. Br J Dermatol 1993; 129: 39–41

    Article  PubMed  Google Scholar 

  77. Hannuksela M, Karvonen J. Topical trioxsalen PUVA therapy. Acta Derm Venereol 1984; Suppl. 113: 135–8

    Google Scholar 

  78. Berne B, Fischer T, Michaelsson G, et al. Long-term safety of trioxsalen bath PUVA treatment: an 8-year follow-up of 149 psoriasis patients. Photodermatol 1984; 1: 18–22

    PubMed  CAS  Google Scholar 

  79. Lindelöf B, Sigurgeirsson B, Tegner E, et al. Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA: a preliminary report. Arch Dermatol 1992; 128: 1341–4

    Article  PubMed  Google Scholar 

  80. Hannuksela A, Pukkala E, Hannuksela M, et al. Cancer incidence among Finnish trioxsalen bath PUVA treated patients. J Am Acad Dermatol 1996; 35: 685–9

    Article  PubMed  CAS  Google Scholar 

  81. Rhodes AR, Harrist TJ, Momtaz T K. The PUVA-induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically, atypical, melanocytes. J Am Acad Dermatol 1983; 9: 47–58

    Article  PubMed  CAS  Google Scholar 

  82. Alcalay J, Bucana C, Kripke ML. Cutaneous pigmented melanocytic tumor in a mouse treated with psoralen plus ultraviolet A radiation. Photodermatol Photoimmunol Photomed 1990; 7: 28–31

    PubMed  CAS  Google Scholar 

  83. Aubin F, Cherrie K, Donawho, et al. Effect of psoralen plus ultraviolet A radiation on in vivo growth of melanoma cells. Cancer Res 1991; 51: 5893–7

    PubMed  CAS  Google Scholar 

  84. Whitmore SE, Morison WL. Melanoma after PUVA therapy for psoriasis. N Engl J Med 1997; 337(7): 502–00

    Article  PubMed  CAS  Google Scholar 

  85. Miller BA, Ries LAG, Hankey BF, editors. SEER cancer statistics review, 1973–1990 [NIH publication no. 93-2789]. Bethesda (MD): National Cancer Institute 1993; I.1–I.2

    Google Scholar 

  86. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1996; 34: 839–47

    Article  PubMed  CAS  Google Scholar 

  87. Stern R. Reply [letter]. N Engl J Med 1997; 337: 503

    Article  Google Scholar 

  88. Elwood JM, Gallagher RP, Stapleton PJ. No association between malignant melanoma and acne or psoriasis: results from the western Canada melanoma study. Br J Dermatol 1986; 115: 573–6

    Article  PubMed  CAS  Google Scholar 

  89. Lindelöf B, Eklund G, Lindén S, et al. The prevalence of malignant tumors in patients with psoriasis. J Am Acad Dermatol 1990; 22: 1056–60

    Article  PubMed  Google Scholar 

  90. Baker H. Methotrexate: the conservative treatment for psoriasis. In: Faber EM, Cox AJ, editors. Psoriasis: Proceedings of the 2nd International Symposium. New York: New York Medical Books, 1977: 235–42

    Google Scholar 

  91. Roenigk HH, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145–6

    Article  PubMed  Google Scholar 

  92. Taylor JR, Halprin KM, Levine V, et al. Effects of methotrexate in vitro on epidermal cell proliferation. Br J Dermatol 1983; 108: 45–61

    Article  PubMed  CAS  Google Scholar 

  93. Zachariae H, Sørgaard H. Methotrexate-induced liver cirrhosis: a follow-up. Dermatologica 1987; 175: 178–82

    Article  PubMed  CAS  Google Scholar 

  94. Roth PE, Grosshans E, Bergoend H. Psoriasis: évolution et complications mortelles [English summary]. Ann Dermatol Venereol 1991; 118: 97–105

    PubMed  CAS  Google Scholar 

  95. Lassus A, Reunala T, Idänpää-Heikkilä J, et al. PUVA treatment and skin cancer: a follow-up study. Acta Derm Venereol 1981; 61: 141–5

    PubMed  CAS  Google Scholar 

  96. Fitzsimons CP, Long J, MacKie RM. Synergistic carcinogenic potential of methotrexate and PUVA in psoriasis. Lancet 1983; I: 235–6

    Article  Google Scholar 

  97. Ott F, Bollag W. Therapie der Psoriasis mit einem oral wirksamen neuen vitamin-A-säure-derivat. Schweiz Med Wochenschr 1975; 105: 439–41

    PubMed  CAS  Google Scholar 

  98. Lowe NJ, Lazarus V, Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol 1988; 19: 186–91

    Article  PubMed  CAS  Google Scholar 

  99. Lowe NJ, Roenigk H, Voorhees JJ. Etretinate: appropriate use in severe psoriasis. Arch Dermatol 1988; 124: 527–8

    Article  PubMed  CAS  Google Scholar 

  100. Morison WL. Etretinate and psoriasis. Arch Dermatol 1987; 123: 879–81

    Article  PubMed  CAS  Google Scholar 

  101. Rosinska D, Wolska H, Jablonska S, et al. Etretinate in severe psoriasis of children. Pediatr Dermatol 1988; 5: 266–72

    Article  PubMed  CAS  Google Scholar 

  102. Shelnitz LS, Esterly NB, Honig PJ. Etretinate therapy for generalised pustular psoriasis in children. Arch Dermatol 1987; 123: 230–3

    Article  PubMed  CAS  Google Scholar 

  103. Goerz G, Orfanos CE. Systemic treatment of psoriasis with a new aromatic retinoid. Dermatologica 1978; 157: Suppl. 1: 38–44

    Article  PubMed  Google Scholar 

  104. McIvor A. Fatal toxic epidermal necrolysis associated with etretinate. BMJ 1992; 304: 548

    Article  PubMed  CAS  Google Scholar 

  105. Mueller W, Herman B. Cyclosporin A for psoriasis [letter]. N Engl J Med 1979; 301: 555

    PubMed  CAS  Google Scholar 

  106. Ellis CN, Gorsulowski DC, Hamilton TA. Cyclosporin improves psoriasis in a double-blind study. JAMA 1986; 256: 3110–6

    Article  PubMed  CAS  Google Scholar 

  107. Griffiths CEM, Powles AV, Leonard JN, et al. Clearance of psoriasis with low dose cyclosporin. BMJ 1986; 293: 731–2

    Article  PubMed  CAS  Google Scholar 

  108. Marks JM. Cyclosporin A treatment of severe psoriasis. Br J Dermatol 1986; 115: 745–6

    Article  PubMed  CAS  Google Scholar 

  109. Meinardi M, Westerhof W, Bos JD. Generalized pustular psoriasis (von Zumbusch) responding to cyclosporin A. Br J Dermatol 1987; 116: 269–70

    Article  PubMed  CAS  Google Scholar 

  110. Mihatsch MJ, Wolff K. Risk benefit ratios of cyclosporin A in psoriasis Br J Dermatol 1990; 122 (Suppl. 36): 1–3

    Google Scholar 

  111. Zachariae H, Kragballe K, Hansen HE, et al. Renal biopsy findings in longterm cyclosporin treatment of psoriasis. Br J Dermatol 1997; 136: 531–5

    Article  PubMed  CAS  Google Scholar 

  112. Bos JD, Meinardi M, van Joost T, et al. Use of cyclosporin in psoriasis. Lancet 1989; II: 1500–2

    Article  Google Scholar 

  113. Weinstein GD, White GM. An approach to the treatment of moderate to severe psoriasis with rotational therapy. J Am Acad Dermatol 1993; 28: 454–9

    Article  PubMed  CAS  Google Scholar 

  114. Edwards R, Wiholm BE, Martinez C. Concepts in risk-benefit assessment: a simple merit analysis of a medicine? Drug Saf 1996; 15: 1–7

    Article  PubMed  CAS  Google Scholar 

  115. Wolff K. Should PUVA be abandoned? N Engl J Med 1997; 336: 1090–1

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Karolinska Hospital and Karolinska Institute, Box 120, S-17176, Stockholm, Sweden

    Bernt Lindelöf (Associate Professor)

Authors
  1. Bernt Lindelöf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lindelöf, B. Risk of Melanoma with Psoralen/Ultraviolet A Therapy for Psoriasis. Drug-Safety 20, 289–297 (1999). https://doi.org/10.2165/00002018-199920040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199920040-00001

Keywords

Search

Navigation